#J. Michael Pearson

Authored by Roddy Boyd via The Southern Investigative Reporting Foundation, Valeant Pharmaceuticals International, the corporate poster-child for price-gouging, tax-inversion and hedge-fund manager wealth destruction quietly severed all ties with J. Michael Pearson, its former chief executive

Pershing Square's Bill Ackman once predicted Valeant would be the next Berkshire Hathaway, saying its shares could hit $330 took a roughly $4 billion loss on the embattled drugmaker as he reported his complete exit overnight. As we detailed previously, the sale ends Mr. Ackman’s quest to rescue

While there was some hope in late 2016 that embattled specialty pharma rollup (which has since become a rolldown) Valeant would sell its Salix stomach-drug business to Takeda, that speculation first fizzled in late November, and then was summarily eliminated when Taked announced yesterday it would

Another day, another round of selling of Valeant stock, which tumbled at the open on a report that the US has announced criminal charges in connection to a Valeant probe and that the ex-CEO of Valeant's "secret pharmacy" Philidor, Andy Davenport as well as another executive, Greg Tanner, have been

The last few weeks have been a wild ride for Valeant shareholders but this morning's comments that the firm "is confident in its forecasts but there may be more surprises" has spooked investors, compounding the fact that the firm missed expectations with sales plunging 11%, and cut its sales and